Concepedia

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

Kenichi Inoue, Kazuhiko Nakagami, Mitsuhiro Mizutani, Yasuo Hozumi, Yasuhiro Fujiwara, Norikazu Masuda, Fumine Tsukamoto, Mitsue Saito, Shigeto Miura, Kenji Eguchi,

Breast Cancer Research and Treatment · 2009 · 89 citations · 10 references

DOI

Concepts

References

10

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +12

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak et al. · New England Journal of Medicine · 2001 · 11.5K citations · Full text

, , +10

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Charles L. Vogel · Journal of Clinical Oncology · 2002 · 3K citations

, , +17

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of <i>HER2</i>-Overexpressing Metastatic Breast Cancer

Charles L. Vogel, Melody Cobleigh, Debu Tripathy et al. · Journal of Clinical Oncology · 2002 · 1.9K citations

, , +15

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Michel Marty, Francesco Cognetti, D Maraninchi et al. · IRIS UNIMORE (University of Modena and Reggio Emilia) · 2005 · 1.6K citations · Full text

, , +17